CommentInduction chemotherapy in head and neck cancer: closer to an answer?
References (7)
- et al.
Chemotherapy added to loco-regional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data
Lancet
(2000) - et al.
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
N Engl J Med
(2007) - et al.
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial
Lancet Oncol
(2011)
Cited by (5)
Laryngo-esophageal dysfunction free survival and propensity score matched analysis comparing organ preservation and total laryngectomy in hypopharynx cancer
2019, Oral OncologyCitation Excerpt :However, their LDFS rate included ‘the presence of natural speech, absence of a tracheostomy, absence of a feeding tube for ≥2 years after treatment or recurring pneumonia that required hospitalization’. Despite the improved results following induction CT with TPF, concerns regarding dose limiting toxicity compromising the concurrent component have prevented this from becoming standard of care [30]. While a recent meta-analysis analyzing induction CT followed by concurrent CRT in head and neck cancer demonstrated a significant improved disease control and complete response rate, they were unable to demonstrate significant improved OS rate in patients treated with induction CT [31].
Neck lymph node metastases from unknown primary
2017, Cancer Treatment ReviewsCitation Excerpt :The concomitant approach has actually became the standard of care in locally advanced head and neck cancer in the past decade. Regimens using TPF (docetaxel, cisplatin, and fluorouracil) may be better than those with PF (cisplatin and fluorouracil) [103,104] but the topic remains debated [105]. As mentioned earlier, it’s been possible to identify two prognostic clinico-pathologic CUP subgroups [106], but the heterogeneous outcome and behaviour is still the distinguishing characteristic of CUP patients.
The emerging era of personalized therapy in squamous cell carcinoma of the head and neck
2011, Asia-Pacific Journal of Clinical Oncology